Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Journal: Clinical pharmacology and therapeutics

Volume: 106

Issue: 4

Year of Publication: 2020

Affiliated Institutions:  Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences University School of Pharmacy, Boston, Massachusetts, USA. Department of Biomedical Data Science, Stanford University, Stanford, California, USA. Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Division of Pharmacogenomics and Personalized Medicine, Faculty of Medicine Ramathibodi Hospital, Department of Pathology, Mahidol University, Bangkok, Thailand. Department of Pharmacy and Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA. Department of Diagnostic & Biomedical Sciences, The University of Texas Health Sciences Center School of Dentistry, Houston, Texas, USA. Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada. African Institute of Biomedical Science & Technology, Wilkins Hospital, Harare, Zimbabwe. Division of Pharmaceutical Sciences, Fairleigh Dickinson University School of Pharmacy, Florham Park, New Jersey, USA. Department of Internal Medicine, Meharry Medical College School of Medicine, Nashville, Tennessee, USA. Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA. Division of Clinical Pharmacology, Toxicology, & Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA.

Abstract summary 

The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.

Authors & Co-authors:  Desta Zeruesenay Z Gammal Roseann S RS Gong Li L Whirl-Carrillo Michelle M Gaur Aditya H AH Sukasem Chonlaphat C Hockings Jennifer J Myers Alan A Swart Marelize M Tyndale Rachel F RF Masimirembwa Collen C Iwuchukwu Otito F OF Chirwa Sanika S Lennox Jeffrey J Gaedigk Andrea A Klein Teri E TE Haas David W DW

Study Outcome 

Source Link: Visit source

Statistics
Citations :  CPIC. CPIC Guideline for Efavirenz based on CYP2B6 genotype <https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype> (2018).
Authors :  17
Identifiers
Doi : 10.1002/cpt.1477
SSN : 1532-6535
Study Population
Male,Female
Mesh Terms
Alkynes
Other Terms
Study Design
Study Approach
Country of Study
Publication Country
United States